… In most complicated cases of COVID-19 infection, the clinical manifestations included fever,
… SP via its tachykinin receptor, NK-1R is responsible for inflammation in COVID-19 infection. It …

… the initiation of cytokine storming developed in Covid-19 infection and we suggest Neurokinin-1
Receptor antagonist, Aprepitant, as a drug to be used for its treatment. It may help in the …

… the initiation of cytokine storming developed in Covid19 infection and we suggest Neurokinin-1
Receptor antagonist, Aprepitant, as a drug to be used for its treatment. It may help in the …

… , may be used to alleviate the symptoms and treat this infection by blocking this nociceptive
… SP/ Neurokinin 1-Receptor may serve as a potential therapeutic strategy against COVID-19 …

… (19). In agreement with these earlier observations, we found that placebo-treated alcoholics
… In addition, the LY686017-treated group showed greater brain activation to the positive …

… The antagonism of tachykinins receptors can be a potential treatment target. … , neuropeptide
γ, haemokinin-1, and endokinins. Tachykinin neurokinin 1 receptors are widely distributed in …

… care recommends a reduced dose of DEX on day 1 without … patients receiving HEC during
the COVID-19 pandemic [25]. … by Cancer Care Ontario in Canada during the COVID-19 …

… for COVID-19 and to examine the data supporting the potential benefits of SAC/VAL in
COVID-19 treatment. … SAC/VAL therapy on COVID-19 severity. We expect a reduced severity of …

… Two naturally occurring variants of the neurokinin 1 receptor (NK1R) mediate the effects
of SP: a ‘classic’ full-length receptor and a truncated (tail-less) form that lacks 96 amino acid …

… with severe Coronavirus Disease 2019 (COVID-19) showed … cells, but not uninfected
cells [1]. It remains to be seen … 1 could be an effective therapy in the fight against COVID-19. …